These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 30589515)

  • 1. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DR4-Ser424
    Lee H; Oh Y; Jeon YJ; Lee SY; Kim H; Lee HJ; Jung YK
    Cancer Res; 2019 Jun; 79(11):2839-2852. PubMed ID: 30987996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation.
    Moriwaki K; Shinzaki S; Miyoshi E
    J Biol Chem; 2011 Dec; 286(50):43123-33. PubMed ID: 22027835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
    Kim SL; Min IS; Park YR; Lee ST; Kim SW
    Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
    Shlyakhtina Y; Pavet V; Gronemeyer H
    Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
    Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
    Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.
    Tse AK; Chow KY; Cao HH; Cheng CY; Kwan HY; Yu H; Zhu GY; Wu YC; Fong WF; Yu ZL
    J Biol Chem; 2013 Oct; 288(41):29923-33. PubMed ID: 23986445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
    Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
    PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.
    Mazurek N; Byrd JC; Sun Y; Hafley M; Ramirez K; Burks J; Bresalier RS
    Cell Death Differ; 2012 Mar; 19(3):523-33. PubMed ID: 21941373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
    Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
    Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
    Bellail AC; Tse MC; Song JH; Phuphanich S; Olson JJ; Sun SY; Hao C
    J Cell Mol Med; 2010 Jun; 14(6A):1303-17. PubMed ID: 19432816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules.
    Hwang MK; Ryu BJ; Kim SH
    Amino Acids; 2012 Oct; 43(4):1679-87. PubMed ID: 22354145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H-Ras regulation of TRAIL death receptor mediated apoptosis.
    Chen JJ; Bozza WP; Di X; Zhang Y; Hallett W; Zhang B
    Oncotarget; 2014 Jul; 5(13):5125-37. PubMed ID: 25026275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.